media – Page 38 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

The tenth batch of national procurement is on the way

With the tenth batch of national procurement about to start, we are once again standing at a new starting point in history, ready to welcome this new wave of reforms in the pharmaceutical industry. On January 9, 2024, the National Medical Security Work Conference was held in Beijing. It was mentioned that the centralized procurement should be promoted to “expand and improve quality”. A new batch of national organized centralized procurement of drugs and consumables will be carried out, and the selected varieties in the centralized procurement will be continued after the expiration of the agreement, so that the total number of national and provincial centralized procurement drugs will reach at least 500, an increase of 50 compared with 2023. In May, the National Medical Insurance Administration issued the “Notice on Strengthening Regional Coordination to Improve the Quality and Expand the Scope of Centralized Procurement of Medicines in 2024”, which ...
- Source: drugdu
- 66
- September 19, 2024
The development of the new OTC market failed miserably! 5 points of retrospective thinking

The announcement of the complete closure of Shenzhen Zhonglian Pharmacy also announced that this once top 100 chain in the country could not withstand the economic downturn and collapsed. It also brought back the author’s memories of developing a new OTC market in Shenzhen many years ago. Shenzhen, the forefront of China’s reform and opening up, the first special economic zone, is not only the “holy land” in the hearts of countless businessmen, but also the place where miracles are born. In August 2001, I was sent to Shenzhen by the company to develop the market due to my outstanding performance at the age of 25. At that time, the company where the author worked was mainly engaged in women’s products (sanitary napkins, panty liners), and its business scope was mainly in the southwest region. Based on the concept of increasing the added value of women’s care products, it developed ...
- Source: drugdu
- 59
- September 19, 2024
Johnson & Johnson’s IL-23 Dual Inhibitor Guselkumab Approved by FDA for Ulcerative Colitis

On September 11, 2024, Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved Tremfya (guselkumab) for the treatment of moderate to severe active ulcerative colitis (UC) in adult patients. The company claims that Tremfya is the first and only dual-action inhibitor targeting interleukin 23 (IL-23) approved for the treatment of active ulcerative colitis, further solidifying Johnson & Johnson’s leadership in the field of inflammatory bowel disease. Guselkumab is the first approved interleukin 23 (IL-23) inhibitor in the world, selectively binding to the p19 subunit of IL-23 to inhibit its interaction with the IL-23 receptor. It has shown strong efficacy for various autoimmune diseases; it can block IL-23 while also binding to the CD64 receptors on cells that produce IL-23. It is currently approved for the treatment of plaque psoriasis, active psoriatic arthritis, and UC. Furthermore, in June 2024, Johnson & Johnson submitted a supplemental Biologics ...
- Source: drugdu
- 68
- September 18, 2024
What’s Next?

Over the past decade, the cross-border medical intermediary industry has experienced a boom, followed by a sharp decline during the pandemic. It has only been after the pandemic that the industry began to recover, but very few companies have managed to endure to this point. Recently, the company Shengnuo Yijia announced a partnership with the Hong Kong Yanghe Medical Group, launching a patient service center in the Yanghe facility to assist critically ill patients from mainland China in seeking medical treatment in Hong Kong. Previously, Shengnuo Yijia focused on bringing patients to the U.S., U.K., Japan, and other overseas regions for treatment. Now, they are increasing efforts to explore the Hong Kong medical market. How should we view this change? According to Shengnuo Yijia Chairman Cai Qiang, cross-border medical services have entered their next phase. The key question remains: Where are the new opportunities in this industry? Seeking Treatment in ...
- Source: drugdu
- 74
- September 18, 2024
Leading the development of antibody drugs! Zhengda Tianqing Nanjing Shunxin Pharmaceutical was recognized as “Nanjing Engineering Research Center”

The “Nanjing Antibody Drug Screening and Transformation Engineering Research Center” built this time aims at the difficulties and pain points of key technologies and results transformation in the process of antibody drug research and development and industrialization. It will build and improve the two key platforms of “core technology breakthrough” and “innovation results transformation” to conduct independent localization research on materials and consumables required for the production of biological products, including cell culture medium, protein chromatography medium and virus removal nanofiltration membrane, and carry out results transformation and industrialization development for key innovative antibodies, antibody-drug conjugates and recombinant humanized proteins. Next, the “Nanjing Antibody Drug Screening and Transformation Engineering Research Center” will further promote the development of biological products and the joint development of upstream and downstream industrial chains, complete the transformation from biosimilars to innovative biological products, develop new antibody drugs with independent intellectual property rights, and ensure the ...
- Source: drugdu
- 114
- September 18, 2024
From minerals to tablets

F Lab is suitable for a wide range of applications, such as feasibility studies, quality control, and troubleshooting during production. The powder analyzer can be used to check the tableting process of a formulation. Users can test raw materials under special conditions and compare various formulations. The compact device can even detect changes in the mineral mixture due to compositional changes. This powder analyzer is therefore a great support for the development of new products. The powder analyzer can be automated and is available in two models: the F Lab 5 with a pressing force of 5 kN for tablets up to 10 mm in diameter, and the F Lab 10 with a pressing force of up to 10 kN for tablets up to 15 mm in diameter. Depending on the customer’s needs, the device can be combined with an automatic data evaluation and display program and other analysis equipment. ...
- Source: drugdu
- 66
- September 18, 2024
【EXPERT Q&A】Do Mexican apis need to be registered separately or in conjunction with preparations?

Drugdu.com expert’s response: The registration requirements for Active Pharmaceutical Ingredients (APIs) in Mexico typically involve a separate registration process, rather than simply being associated with the registration of the final dosage form. This is because APIs, as the essential components of dosage forms, have a direct impact on the quality, safety, and efficacy of the final product. Registration Requirements for APIs in Mexico Approval from the Mexican Ministry of Health: The export of APIs to Mexico requires approval from the Mexican Ministry of Health. This signifies that APIs must comply with Mexico’s local pharmaceutical regulations and standards. COFEPRIS Registration: Manufacturers of APIs need to register with the Federal Commission for the Protection against Sanitary Risks (COFEPRIS), which is the primary agency under the Mexican Ministry of Health responsible for regulating drugs, medical devices, cosmetics, and hygiene products. During the registration process, companies must submit a range of documents, including but not limited ...
- Source: drugdu
- 65
- September 18, 2024
The Heyuan Hemei Regenerative Medicine Center has been officially established, and Heyuan Biotech is embarking on a new journey with the wind

On September 13th, as the autumn atmosphere grew stronger, the establishment ceremony of Heyuan Hemei Regenerative Medicine Center was successfully held at 3888 Canghai Road and Heyuan Intelligent Manufacturing Precision Medical Industry Base in Lingang New Area, Shanghai. At the event, all the guests gathered together to witness this milestone moment.The successful holding of the establishment ceremony of Heyuan and Hemei marks a further expansion of Heyuan Group’s business map and a solid step forward in the strategic layout of cell therapy. As a high-tech enterprise deeply involved in the fields of cell and gene therapy, Heyuan Group relies on its own nearly 5000 square meters of comprehensive research and development production platform, as well as nearly 80000 square meters of port base, to continuously accelerate the research and commercialization process of cell and gene therapy. The establishment of Heyuan Hemei Regenerative Medicine Center will help enterprises build a more ...
- Source: drugdu
- 68
- September 18, 2024
P-MEC Asia

Organiser：Informa Markets Time：July 16th – 18th, 2025 address：Kompleks MITEC @ KL Metropolis, 8, Jalan Dutamas 2, Segambut, 50480 Kuala Lumpur, Federal Territory of Kuala Lumpur, Malaysia Exhibition hall：Malaysia International Trade and Exhibition Centre (MITEC) Product range: Pharmaceutical Raw Material Equipment: Reactors, Drying Equipment, Crystallization Equipment, Centrifuges, Extraction Equipment, Heat Exchangers, Storage Equipment, Filtration Equipment, Evaporation Equipment, Distillation Equipment, Screening Machinery, Filter Presses, Homogenizers, etc. Pharmaceutical Preparation Equipment: Pill Machinery, Ointment Machinery, Eye Drop Machinery, Tablet Machinery, Tincture & Syrup Machinery, Instant Granule Machinery, Soft Capsule Machinery, Aqueous Injection Machinery, Hard Capsule Machinery, Suppository Machinery, Oral Liquid Machinery, Pharmaceutical Film Machinery, Aerosol Machinery, Powder & Aqueous Injection Machinery, Infusion Machinery, Tablet Presses, Coating Machines, Pharmaceutical Filling Machines, Jet Mills, Pharmaceutical Grinders, Low-Temperature Grinders, Pharmaceutical Grinding Units, Mechanical Pharmaceutical Grinders, Ultra-fine Grinders, Granulators, Mixing Equipment, Bottle Conveyors, Bottle Sorting Machines, Bottle Washers, Aeration Devices, Oscillating Cappers, Feeding Devices, etc. Pharmaceutical Packaging Machinery: ...
- Source: drugdu
- 199
- September 17, 2024
$1.8 billion! Lilly builds factory and expands GLP-1 production

Disclaimer: Due to limited proficiency, errors are inevitable, or some information may not be timely. Please feel free to leave a message to indicate. This article only provides an introduction to medical and health-related drugs, and does not recommend treatment plans (if applicable); This article does not constitute any investment advice. Lilly said that the company had completed the $800 million Kinsale factory expansion project to increase the production of its obesity and diabetes drugs Mounjaro and Zepbound. At the same time, the pharmaceutical company will also invest $1 billion to build a factory in Limerick to increase the production of biopharmaceutical raw materials, especially Kisunla, a drug approved by the FDA to treat Alzheimer’s disease two months ago. The production of active pharmaceutical ingredients is expected to begin in 2026. Lilly stated that Limerick’s expansion will add tools for artificial intelligence, automated robots, and machine learning to the website. ...
- Source: drugdu
- 74
- September 16, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.